Imaging endpoints for clinical trial use: a RECIST perspective
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005092
Abstract: Twenty years after its initial introduction, Response Evaluation Criteria in Solid Tumors (RECIST) remains today a unique standardized tool allowing uniform objective evaluation of response in solid tumors in clinical trials across different treatment indications.… read more here.
Keywords: trial use; recist; clinical trial; imaging endpoints ... See more keywords